3.12
-0.09(-2.80%)
Currency In USD
| Previous Close | 3.21 |
| Open | 3.19 |
| Day High | 3.19 |
| Day Low | 3.1 |
| 52-Week High | 4.97 |
| 52-Week Low | 1.75 |
| Volume | 53,154 |
| Average Volume | 85,829 |
| Market Cap | 43.15M |
| PE | -4.11 |
| EPS | -0.76 |
| Moving Average 50 Days | 3.12 |
| Moving Average 200 Days | 2.99 |
| Change | -0.09 |
If you invested $1000 in Grace Therapeutics, Inc. (GRCE) since IPO date, it would be worth $1,036.54 as of October 18, 2025 at a share price of $3.12. Whereas If you bought $1000 worth of Grace Therapeutics, Inc. (GRCE) shares 1 year ago, it would be worth $1,036.54 as of October 18, 2025 at a share price of $3.12.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
GlobeNewswire Inc.
Sep 22, 2025 12:00 PM GMT
Presentation Highlighted Data Supporting Clinical Benefit of GTx-104 Compared to Orally Administered Nimodipine in the Treatment of aneurysmal Subarachnoid Hemorrhage (aSAH)PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
GlobeNewswire Inc.
Sep 18, 2025 12:30 PM GMT
Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics,
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 12:00 PM GMT
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being